| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
|
Purity: ≥98%
Indomethacin (Indometacin; Indocin) is a potent and non-selective COX1 and COX2 inhibitor of the nonsteroidal anti-inflammatory drug (NSAID) class with an IC50 of 0.1 μg/mL and 5 μg/mL, respectively. Indomethacin is a synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties and is used to reduce fever, pain, stiffness, and swelling. Indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines.
| ln Vitro |
In vitro antitumor activity of indomethacin (Indometacin) (0-150 μM; 24 hours; 3LL-D122 cells) has been reported [2]. By activating PKR and phosphorylating eF2α, indomethacin (Indometacin) (0-1000 μM) inhibits viral replication (IC50=2 μM) and stops viral protein translation, protecting host cells from viral harm [3]. M1 type RAW 264.7 cells undergo M2 type differentiation when exposed to 8 μM of indomethacin for 26 hours [4]. Human adipose-derived stem cells undergo transdifferentiation into neurogenic-like cells when exposed to indomethacin (200 μM) for five days [5].
|
|---|---|
| ln Vivo |
Using indomethacin, models of gastrointestinal ulcers can be created in animals.
|
| Animal Protocol |
Animal/Disease Models: Male SD (Sprague-Dawley) rats[1]
Doses: 0.01-10 mg/kg Route of Administration: Oral administration; for 3 hrs (hours) Experimental Results: Inhibited the carrageenan-induced rat paw oedema (ED50=2.0 mg/kg) and hyperalgesia (ED50= 1.5 mg/kg) in a dose-dependent manner. Animal/Disease Models: Male C57BL/6J mice[2] Doses: 10 mg/mL Route of Administration: Oral administration; daily, for 29 days Experimental Results: Delayed the onset of tumor growth and the initial growth rate of the footpad tumors. |
| References |
[1]. Riendeau D, et, al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17.
[2]. Eli Y, et, al. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol. 2001 Mar 1;61(5):565-71. [3]. Amici C, et, al. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR. Cell Microbiol. 2015 Sep;17(9):1391-404. [4]. Luo X, Xiong H, Jiang Y, et al. Macrophage Reprogramming via Targeted ROS Scavenging and COX-2 Downregulation for Alleviating Inflammation. Bioconjug Chem. 2023;34(7):1316-1326. [5]. Kompisch KM, Lange C, Steinemann D, et al. Neurogenic transdifferentiation of human adipose-derived stem cells? A critical protocol reevaluation with special emphasis on cell proliferation and cell cycle alterations. Histochem Cell Biol. 2010;134(5):453-468. |
| Molecular Formula |
C19H16CLNO4
|
|
|---|---|---|
| Molecular Weight |
357.79
|
|
| CAS # |
53-86-1
|
|
| Related CAS # |
Indomethacin;53-86-1;Indomethacin sodium hydrate;74252-25-8
|
|
| SMILES |
ClC1C([H])=C([H])C(=C([H])C=1[H])C(N1C(C([H])([H])[H])=C(C([H])([H])C(=O)O[H])C2C([H])=C(C([H])=C([H])C1=2)OC([H])([H])[H])=O
|
|
| InChi Key |
CGIGDMFJXJATDK-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
|
|
| Chemical Name |
2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7949 mL | 13.9747 mL | 27.9494 mL | |
| 5 mM | 0.5590 mL | 2.7949 mL | 5.5899 mL | |
| 10 mM | 0.2795 mL | 1.3975 mL | 2.7949 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA